KRAS and neoplasm: rTIMP2-treated tumor-bearing wt mice exhibit gene expression changes that focus on the downregulation of oncogenic pathways such as EIF2 signaling and cell cycle control of chromosomal replication, a result of reduced activity of upstream oncogene drivers such as Myc, Kras, and Tgfb, and enhanced activity of the tumor suppressors p53 and Ctnnb1 (Beta-catenin).